Nabriva Therapeutics plc (NBRV) has a consensus analyst rating of Hold, based on 10 analysts covering the stock. Of those, 4 recommend buying, 5 recommend holding, and 1 recommend selling.
The analyst consensus price target for NBRV is $1.00, representing a -29.6% downside from the current price of $1.42. Price targets range from a low of $1.00 to a high of $1.00.
